Placebo-Controlled Trial of Oral Laquinimod for Multiple SclerosisGıancarlo Comı, Massimo Filippi, Douglas Jeffery et al.|New England Journal of Medicine|2012Cited by 362
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Michelle Mellion et al.|The Lancet Neurology|2019Cited by 185
Aggressive multiple sclerosis (1): Towards a definition of the phenotypeEllen Iacobaeus, Emmanuelle Waubant, Georgina Arrambide et al.|Multiple Sclerosis Journal|2020Cited by 79
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021Carmen Tur, Bruno Stankoff, Anat Achiron et al.|Multiple Sclerosis Journal|2022Cited by 46